Program
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207
Also written as “WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab” and “JS207”.
Its studies are led by 2 companies.
Drug pageAnti-PD-1/Anti-VEGF Bispecific Antibody JS207: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mabwell (Shanghai) Bioscienceits history only | 11 open or running | phase 2since Mar 8, 2026 | Mar 8, 2026 | Dec 31, 2027phase 2 · NCT07466160 |
| Wigen Biomedicine Technology (Shanghai)its history only | 11 open or running | phase 2since Apr 23, 2025 | Apr 23, 2025 | Jun 30, 2029phase 2 · NCT06953323 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 23, 2025First study: phase 2 study in Advanced Solid TumorNew to Wigen Biomedicine Technology (Shanghai)Wigen Biomedicine Technology (Shanghai) · NCT06953323 · 86 planned · China
- Mar 8, 2026Mabwell (Shanghai) Bioscience’s first study: phase 2 study in Solid TumorNew to Mabwell (Shanghai) BioscienceMabwell (Shanghai) Bioscience · NCT07466160 · 280 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Solid TumorMabwell (Shanghai) Bioscience · NCT07466160
- Jun 30, 2029Primary completion: phase 2 study in Advanced Solid TumorWigen Biomedicine Technology (Shanghai) · NCT06953323
TargetBeta
“A recombinant humanized bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07466160Solid Tumor · China | 2 | Recruiting | Mabwell (Shanghai) Bioscience | Dec 31, 2027 | 280 |
| NCT06953323Advanced Solid Tumor · China | 2 | Recruiting | Wigen Biomedicine Technology (Shanghai) | Jun 30, 2029 | 86 |
How it is read
Names in the registry
- “WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab”, 1 entry
- “JS207”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.